Kindred Biosciences, Inc.
) plunged 28.2% as a pivotal field study on its pipeline candidate
CereKin (interleukin-1 inhibitor) failed to meet the primary
endpoint. Although the company recovered a nominal 0.2% in the
subsequent trading session, shares are still down 28% since the
Kindred Biosciences announced top-line data from a pivotal study
(KB010) evaluating CereKin for the treatment of pain and
inflammation in dogs suffering from osteoarthritis.
The randomized, double-blind, placebo-controlled study evaluated
the safety and efficacy of two doses of CereKin. The study missed
the primary endpoint of a statistically significant improvement in
the response rate compared to placebo.
Kindred Biosciences intends to submit detailed data at a
forthcoming scientific meeting.
Kindred Biosciences also provided an update on its pipeline
candidates. The company continues to enroll patients in pivotal
studies being conducted on AtoKin (treatment of atopic dermatitis
in dogs) and SentiKin (treatment of post-operative pain in dogs).
Positive results from these studies would allow Kindred Biosciences
to file New Animal Drug Applications for marketing approval of
AtoKin and SentiKin in the U.S. in 2014. This could be followed by
a potential product launch as early as the end of 2015.
Kindred Biosciences has completed a pharmacokinetic (PK) study
on extended-release SentiKin for post-operative pain in cats. A PK
study of a drug for the stimulation of appetite in cats has
commenced with a study for fever in horses expected to start this
The company also announced significant progress in its biologics
programs, which include erythropoietin for cats with anemia and
immune checkpoint inhibitors for dogs with cancer.
We are disappointed with the pipeline setback pertaining to CereKin
at Kindred Biosciences. We expect investor focus to remain on the
company's progress with its pipeline.
Kindred Biosciences is a Zacks Rank #3 (Hold) stock. Some
better-ranked stocks in the biotech sector include Amgen Inc. (
), Cambrex Corp. (
) and China Biologic Products, Inc. (
). All three hold a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
KINDRED BIOSCI (KIN): Free Stock Analysis
AMGEN INC (AMGN): Free Stock Analysis Report
CAMBREX CORP (CBM): Free Stock Analysis Report
CHINA BIOLOGIC (CBPO): Get Free Report
To read this article on Zacks.com click here.